Organ-specific autoimmunity

Current Opinion in Immunology

Volumn 9, Issue 6, 1997, Pages 863-871

  King, Cecile ^a   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; GENETIC SUSCEPTIBILITY; HELPER CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0031445896     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80191-4     Document Type: Article

References (75)

1. Mason D, Fowell D: T-cell subsets in autoimmunity. Curr Opin Immunol 1992, 4:728-732.
2. Saoudi A, Seddon B, Heath V, Fowell D, Mason D: The physiological role of regulatory T cells in the prevention of autoimmunity: the function of the thymus in the generation of the regulatory T cell subset Immunol Rev 1996, 149:195-216.
3. Saoudi A, Seddon B, Fowell D, Mason O: The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med 1996, 184:2393-2398.
4. Barrett SP, Gleeson PA, de Silva H, Toh BH, van Driel IR: Interferon-gamma is required during the initiation of an organ-specific autoimmune disease. Eur J Immunol 1996, 26:1652-1655.
5. Bohme J, Schuhbauer B, Kanagawa O, Benoist C, Mathis D: MHC-linked protection from diabetes associated with clonal deletion of T cells. Science 1987, 249:293-295.
6. Macaulay AE, DeKruyff RH, Goodnow CC, Umetsu DT: Antigen specific B cells preferentially induce CD4+ T cells to produce IL-4. J Immunol 1997, 158:4171-4179.
7. Garza KM, Griggs ND, Tung KS: Neonatal injection of an ovarian •• peptide induces autoimmune ovarian disease in female mice: requirement of endogenous neonatal ovaries. Immunity 1997, 6:89-96. When neonatal female (C57BL/6 × A/J)F1 mice are injected with an ovarian (ZP3) peptide, autoimmune ovarian disease (OAD) develops at 5 weeks of age. The presence of endogenous antigen at the time of initial priming is essential for the development of a pathogenic autoimmune response as male mice injected neonatally with the same peptide become tolerant to it, and this tolerant state is an antigen specific Th2-deviated response. The autoimmune response (to subsequent ovarian grafts) following neonatal injection is abrogated in female mice that have been neonatally ovarectomised and their T-cell response becomes Th2 dominant. The critical time window ovarectomy effects supports the likelihood that endogenous ovarian antigens are not ignored but are normally perceived by the neonatal immune system.
8. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D, Swain SL: Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997, 185:1837-1849.
9. Itoh A, Maki T: Protection of nonobese diabetic mice from autoimmune diabetes by reduction of islet mass before insulitis. Proc Natl Acad Sci USA 1996, 93:11053-11056.
10. Kaufman DL, Clare-Salzer M, Tian J, Forsthuber T, Ting G, Robinson G, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993, 366:69-72.
11. Tisch R, Yang S-D, Singer SM, Liblau RS, Fugger L, McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993, 366:72-75.
12. Wang Y, Pontesilli O, Gill RG, La Rosa FG, Lafferty KJ: The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991, 88:527-531.
13. Gazda LS, Charlton B, Lafferty KJ: Diabetes results from a late change in the autoimmune response of NOD mice. J Autoimmun 1997, 10:261-270.
14. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D: Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87:811-822.
15. Sarvetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, Gregory A, Parslow T, Stewart T: Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990, 346:844-847.
16. Mueller R, Krahl T, Sarvetnick N: Pancreatic expression of • interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996, 184:1093-1099. Transgenic NOD mice that express IL-4 in the pancreatic islets under the control of the human insulin promoter are completely protected from the development of insulitis and diabetes. These mice are not susceptible to disease induction via adoptive transfer of diabetogenic T cells, but islet expression of IL-4 was unable to prevent islet rejection in overtly diabetic recipients. These findings suggest an effect of IL-4 on the early stages of the development of autoimmunity in NOD mice.
17. Miller JFAP, Heath WR: Self ignorance in the peripheral T cell pool, Immuno Rev 1993, 133:131-150.
18. Dubey C, Croft M, Swain SL: Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol 1996, 157:3280-3289.
19. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA • Jr, Flavell RA: Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of autoreactive islet-specific T cells [see comments]. J Exp Med 1996, 184:1963-1974. See annotation to [16*]. Expression of TNF-α in the islets of Langerhans directed by the rat insulin promoter protects NOD mice from the development of diabetes. These mice succumb to diabetes upon receiving diabetogenic splenocytes, display a selective lack of T-cell reactivity to islet antigens and the findings are consistent with a defect in T-cell priming to islet antigens.
20. Guerder S, Meyerhoff J, Flavell R: The role of the T cell costimulator B7-1 In autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994, 1:155-166.
21. + T cells. J Exp Med 1997, 186:239-245. This study used a transgenic model in which OVA-specific transgenic CD8+ T cells were injected into unirradiated transgenic RIP-mOVA mice, which express a membrane form of OVA (mOVA) in pancreatic islet β cells and in renal proximal tubular cells, the thymus and in the testis. The findings indicate an extrathymic mechanism that can induce the deletion of CD8+ cells responding to autoantigen expressed in tissues outside the lymphoid compartment. Self antigens are presented, not by the tissues themselves, but by professional APCs in the context of MHC class I via a constitutive exogenous cross-over processing pathway.
22. Cua DJ, Coffman RL, Stohlman SA: Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. J Immunol 1996, 157:2830-2836.
23. Sarvetnick N: Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med 1996, 184:1597-1600.
24. Mueller R, Bradley LM, Krahl T, Sarvetnick N: Mechanism underlying counter-regulation of autoimmune diabetes by IL-4. Immunity 1997, 7:411-418.
25. Pearson Cl, van Ewijk W, McDevitt HO: Induction of apoptosis • and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice. J Exp Med 1997, 185:583-599. Transgenic mice were developed that express a T-cell receptor specific for the amino-terminal peptide (Ac1-11) of MBP. This study investigates the mechanisms of soluble peptide therapy in EAE and shows that a therapeutic peptide with high affinity for the MHC induces apoptosis and protective Th2 subset differentiation.
26. Moudgil KM, Chang TT, Eradat H, Chen AM, Gupta RS, Brahn •• E, Sercarz EE: Diversification of T cell responses to carboxyterminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. J Exp Med 1997, 185:1307-1316. This study investigates the diversification of T-cell responses to Bhsp65 in relation to the development of arthritis in susceptible (Lewis) and resistant (WKY) rodent strains with the same MHC class II molecules. Diversification of the T-cell response to the carboxy-terminal determinants of Bhsp65 appears to be involved in protection from autoimmune arthritis. Importantly, the natural trend of diversification in the resistant strain can be approached therapeutically in the susceptible strain via immunization with peptides comprising the carboxy-terminal region of Bhsp65.
27. + T cells. Eur J Immunol 1992, 22:1013-1022.
28. + T cells is markedly increased via the crossing of RIP-HA mice with TCR HA transgenic mice, diabetes develops neonatally.
29. Ito K, et al.: HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996, 183:2635-2644.
30. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, McDevitt HO, Lo D: A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994, 1:73-83.
31. Dalal M, Kim S, Voskuhl RR: Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 1997, 159:3-6.
32. Segal BM, Shevach EM: IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996, 184:771-775.
33. Sun B, Rizzo LV, Sun SH, Chan CC, Wiggert B, Wilder RL, Caspi RR: Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 1997, 159:1004-1111.
34. Conby IM, DeKruyff RH, Tate KM, Cao ZA, Moore TA, Umetsu DT, Jones PJ: Novel genetic regulation of T helper (TH1)/Th2 cytokine production and encephalogenicity in inbred mouse strains. J Exp Med 1997, 3:439-451.
35. Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MBA: Primary demyelination in transgenic mice expressing interferon-γ. Nat Med 1997, 3:1037-1041.
36. von Herrath MG, Dockter J, Oldstone MBA: How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994, 1:231-242.
37. von Herrath MG, Oldstone MBA: Interferon-g is essential for destruction of b cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997, 185:531-539.
38. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier MC, Fournier C: High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501-5506.
39. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR: IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997, 158:5997-6005.
40. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P: Accelerated collagen-induced arthritis in IFN-gamma receptor deficient mice. J Immunol 1997, 158:5507-5513.
41. Kumar V, Stellrecht K, Sercarz E: Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J Exp Med 1996, 184:1609-1617.
42. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA: IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996, 157:3223-3227.
43. Krakowski M, Owens T: Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
44. Liu Y, Janeway CA: Interferon γ plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 1990, 172:1735-1739.
45. Seder RA, Gazzineli R, Sher A, Paul WE: Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993, 90:10188-10192.
46. Rogge L, Barberis-Maino L, Biffi M, Passini N, Preskey DH, Bugler U, Sinigaglia F: Selective expression of an interleukin-12 receptor component by human T helper cells. J Exp Med 1997, 5:825-831.
47. Szabo SJ, Anand DS, Gubler U, Murphy KM: Regulation of the interleukin (1L)-12R β2 subunit expression in developing T helper 1 (TH1) and Th2 cells. J Exp Med 1997, 185:817-824.
48. + T cells in patients with progressive multiple sclerosis.
49. Segal BM, Klinman DM, Shevach EM: Microbial products induce • autoimmune disease by an IL-12-dependent pathway. J Immunol 1997, 158:5087-5090. The exposure of T cells that recognise MBP to the bacterial cell wall compartment LPS, or to highly purified bacterial DNA is shown to result in a pathogenic Th1 response, providing evidence for a mechanism by which infectious agents might precipitate inflammatory autoimmune disease.
50. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental autoimmune encephalomyelitis. J Exp Med 1990, 172:1193-1200.
51. Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fontana A: Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997, 185:2177-2182.
52. Steinman L: Some misconceptions about understanding autoimmune through experiments with knockouts. J Exp Med 1997, 185:2039-2041.
53. Balasa B, Deng C, Lee J, Bradley LM, Dalton D, Christadoss • P, Sarvetnick N: IFN-g is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune Myasthenia Gravis in mice. J Exp Med 1997, 186:385-391. This paper highlights the importance of IFN-γ in the development of humoral autoimmunity. Antibody response to AChR in IFN-γ KO mice were not demonstrated but an IgG1 response was detected when immunised with a foreign antigen (KLH). The investigators suggest that the difference in response to self-antigen and foreign antigen is due to differences in T-cell affinities. This may result in differential requirements for IFN-γ in the stimulation of B cells for differentiation and subsequent antibody production during cognitive T-B cell interactions.
54. β 8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J Exp Med 1997, 185:1725-1733.
55. Webb L, Feldmann M: Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Blood 1995, 86:3479-3486.
56. Chambers CA, Allison JP: Co-stimulation in T cell responses. Curr Opin Immunol 1997, 9:396-404.
57. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, • Fuchs E, Singh B, Thompson CB, Bluestone JA: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes [Erratum: Immunity 1997, 6:215]. Immunity 1996, 5:285-293. This study extends our understanding of the importance of the effects of CD28/B7 interactions in Th2 subset differentiation and in delaying the progression of autoimmune disease.
58. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW: CD28-B7 costimulatory blockade by CTLA4lg prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995, 155:4521-4524.
59. Arima T, Rehman A, Hickey WF, Flye MW: Inhibition by CTLA4 Ig of experimental allergic encephalomyelitis. J Immunol 1996, 156:4916-4924.
60. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996, 157:1333-1336.
61. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH: Ex vivo treatment of antigen-presenting cells with CTLA4 Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996, 157:3700-3705.
62. Grewal IS, Xu J, Flavell RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1996, 378:617-620.
63. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron •• JL, Janeway CA Jr, Flavell RA: Requirement for CD40 ligand in costimulation induction, T cell activation and experimental allergic encephalomyelitis. Science 1996, 273:1864-1867. The investigators propose a two-step model for T-cell activation in response to self antigen, including a regulatory step where activation of the APC primed with the cognate antigen is by the T cell specific for that antigen.
64. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N: CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997, 159:4620-4627.
65. Mathisen PM, Yu M, Johnson JM, Drazba JA, Tuohy VK: Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997, 186:159-164.
66. Shaw MK, Lorens JB, Dhawan A, DalCanto R, Tse HY, Tran AB, Bonpane C, Eswaran SL, Brocke S, Sarvetnick N: Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997, 185:1711-1714.
67. Falcone M, Bloom BR: A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med 1997, 185:901-907.
68. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington •• C, Raine CS, Hauser SL: Late complications of immune deviation therapy in a nonhuman primate. Science 1996, 274:2054-2057. This study shows that immune deviation therapy that enhances Th2 cell responses can increase concentrations of pathogenic autoantibodies which exacerbate disease.
69. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR: Induction •• of autoimmune diabetes by oral administration of autoantigen. Science 1996, 274:1707-1709. This study cautions against the use of oral tolerance to deviate autoaggressive T-cell responses to protective T-cell responses. Feeding C57BL/6 (B6) mice with one large dose of OVA was shown to result in the generation of CTL responses.
70. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1188.
71. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, • Tonegawa S: Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997, 186:307-312. MBP protein-specific Th2 cells, generated in vitro, can transfer EAE to RAG-1 KO and TCR αβ-deficient mice but not normal or γδ T-cell deficient mice, suggesting that αβ T cells are involved in downregulation of the autoaggressive Th2 response.
72. Pakala SV, Kurrer MO, Katz JD: T helper 2 (Th2) T cells induce • acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 1997, 186:299-306. Th2 effectors from BDC2.5 mice are able to transfer autoimmune disease into NOD-scid recipients. The resulting disease resembles that of allergic inflammation and is mediated by IL-10 production.
73. Rajan AJ, Gao Y-L, Raine C, Brosnan C: A pathogenic role for y5 T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J Immunol 1996, 157:941-949.
74. Lee MS, Mueller R, Wicker LS, Peterson LB, Sarvetnick N: IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 1996, 183:2663-2668.
75. Bridoux F, Badou A, Saoudi A, Bernard I, Druet E, Pasquier R, Druet P, Pelletier L: Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J Exp Med 1997, 185:1769-1775.